Studies of guidelines-based optimal heart failure medical therapy using angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), beta receptor blocking agents (β-blockers) and mineralocorticoid receptor antagonists (MRA) have demonstrated that improved clinical outcomes of HFrEF patients were associated with the reverse remodeling of the failing myocardium [4] which largely predicated on the inhibition of renin–angiotensin–aldosterone axis. This evidence concerns the gene ACE and heart failure.